TABLE 3.

Cardiometabolic health parameters¹

	Placebo	NR	Change	P value
MRS cardiac left ventricle2
Cardiac PCr:ATP ratio	1.29 ± 0.11	1.22 ± 0.09	−0.08 ± 0.14	0.90
MRI cardiac left ventricle3
EF, %	71.2 ± 2.2	68.2 ± 2.1	−3.0 ± 2.4	0.24
ESV, mL	35.0 ± 4.2	38.9 ± 3.9	4.0 ± 3.6	0.23
EDV, mL	119.4 ± 8.2	121.2 ± 8.3	1.8 ± 5.1	0.72
SV, mL	84.4 ± 5.6	82.3 ± 5.6	−2.1 ± 3.8	0.69
Ambulatory BP 36-h3
SBP, mm Hg	124.6 ± 2.4	126.6 ± 3.2	2.0 ± 2.3	0.56
DBP, mm Hg	77.1 ± 1.8	77.9 ± 2.0	0.8 ± 0.9	0.39
MAP, mm Hg	98.9 ± 1.7	100.2 ± 2.1	1.3 ± 1.5	0.40
PP, mm Hg	47.5 ± 2.6	48.6 ± 3.1	1.2 ± 2.2	0.60
HR, bpm	76.4 ± 3.3	75.5 ± 3.6	−0.9 ± 1.7	0.60
Nighttime dipping SBP, %	10.6 ± 2.4	12.4 ± 0.8	1.8 ± 2.8	0.53
Nighttime dipping DBP, %	11.9 ± 2.4	14.8 ± 1.9	3.0 ± 2.5	0.26
Ambulatory BP daytime
SBP, mm Hg	126.9 ± 2.3	129.0 ± 2.9	2.1 ± 2.3	0.54
DBP, mm Hg	79.5 ± 1.7	80.5 ± 1.9	1.0 ± 1.0	0.32
MAP, mm Hg	101.4 ± 1.5	102.7 ± 1.9	1.3 ± 1.4	0.39
PP, mm Hg	47.6 ± 2.7	48.5 ± 3.0	0.9 ± 2.1	0.68
HR, bpm	78.3 ± 3.2	77.5 ± 3.5	−0.8 ± 1.7	0.67
Ambulatory BP night-time3
SBP, mm Hg	113.5 ± 3.4	113.0 ± 3.1	−0.5 ± 3.7	0.90
DBP, mm Hg	69.4 ± 2.6	68.1 ± 2.3	−1.3 ± 1.5	0.41
MAP, mm Hg	89.6 ± 2.7	88.8 ± 2.4	−0.8 ± 2.5	0.75
PP, mm Hg	43.8 ± 2.5	45.2 ± 2.6	1.4 ± 2.3	0.57
HR, bpm	65.6 ± 2.5	66.6 ± 2.9	1.0 ± 1.9	0.60

¹Values are means ± SEs. P values are derived from the analysis of the mean within-person changes and the SE of the within-group changes. BP, blood pressure; DBP, diastolic blood pressure; EDV, end diastolic volume; EF, ejection fraction; ESV, end systolic volume; HR, heart rate; MAP, mean arterial pressure; NR, nicotinamide riboside; PCr, phosphocreatin; PP, pulse pressure; SBP, systolic blood pressure; SV, stroke volume.

² n = 11.

³ n = 12.